Clinical and Translational Oncology

, Volume 12, Issue 6, pp 418–430 | Cite as

Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting

  • Antonio González-MartínEmail author
  • Gemma Toledo
  • Luis Chiva
Educational Series Multidisciplinary Approach to Cancer Treatment


Epithelial ovarian carcinoma is still the most common cause of death from gynaecological cancer in USA and western Europe. The optimal therapy of epithelial ovarian carcinoma requires participation of a multidisciplinary team — from diagnosis through the entire natural history of each individual patient. Only 20–30% of patients are diagnosed at the initial stage, when appropriate staging surgery in combination with adjuvant chemotherapy for high-risk patients can be curative. Treating patients with advanced disease consists of a staging surgery with maximum cytoreductive effort, followed by chemotherapy with a combination of taxane and carboplatin. Unfortunately, the majority of patients with advanced disease will relapse and become candidates for therapy that comprises individualised chemotherapy, and surgery in selected cases. For this reason, there is still a need for new treatments and strategies in the first-line setting.


Epithelial ovarian cancer First-line therapy Evidence-based medicine Advanced ovarian carcinoma Early-stage ovarian carcinoma Chemotherapy Surgery Pathology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Siegel R, Ward E et al (2010) Cancer statistics 2009. CA Cancer J Clin 59:225–249CrossRefGoogle Scholar
  2. 2.
    Goff BA, Mandel Lynn, Muntz HG, Melacon CH (2004) Ovarian carcinoma diagnosis. Results of a Frecuency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705–2712CrossRefPubMedGoogle Scholar
  3. 3.
    Vergote I, De Brabanter J, Fyles A et al (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian cancer. Lancet 357:176–182CrossRefPubMedGoogle Scholar
  4. 4.
    Trimbos JB, Parmar M, Vergote I et al (2003) International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Nat Cancer Inst 95:105–112CrossRefPubMedGoogle Scholar
  5. 5.
    Hennessy BT, Coleman R, Markman M (2009) Ovarian cancer. Lancet 374(9698):1371–1382CrossRefPubMedGoogle Scholar
  6. 6.
    Poveda A, Casado A, Cervantes A et al (2007) Treatment guidelines in ovarian cancer. Clin Transl Oncol 9:308–316CrossRefGoogle Scholar
  7. 7.
    Gonzalez-Martin A (2005) Treatment of recurrent disease: randomized trials of monotherapy versus combination therapy. Int J Gynecol Cancer 15(Suppl 3):241–246CrossRefPubMedGoogle Scholar
  8. 8.
    Medeiros LR, Rosa DD, Bozetti MD et al (2009) Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database Syst Rev Apr 15(2):CD00475Google Scholar
  9. 9.
    Medeiros LR, Rosa DD, Bozetti MD et al (2008) Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev Oct 8(4):CD005344Google Scholar
  10. 10.
    Tavassoli FA, Devilee P eds (2003) World Health Organization Classification of Tumours. Pathology and genetics of tumours of breast and female genital organs. IARC Press, LyonGoogle Scholar
  11. 11.
    Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7–15CrossRefPubMedGoogle Scholar
  12. 12.
    Movahedi-Lankarani S, Baker PM, Gilks CB et al (2009) Protocol for the examination of specimens from patients with carcinoma of the ovary. College of American Pathologists (CAP) Cancer Protocols. Available at Accessed on May 30, 2010
  13. 13.
    McCluggage WG (2008) My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 61:152–163CrossRefPubMedGoogle Scholar
  14. 14.
    Soslow RA (2008) Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27:161–174PubMedGoogle Scholar
  15. 15.
    Malpica A, Deavers MT, Tornos C et al (2007) Interobserver and intraobserver variability of a twotier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1168–1174.CrossRefPubMedGoogle Scholar
  16. 16.
    Baker PM, Oliva E (2005) Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol 24:39–55PubMedGoogle Scholar
  17. 17.
    Prat J (2005) Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol 18(Suppl 2):S99–S111CrossRefPubMedGoogle Scholar
  18. 18.
    Gilks CB, Prat J (2009) Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 40:1213–1223CrossRefPubMedGoogle Scholar
  19. 19.
    Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415–428CrossRefPubMedGoogle Scholar
  20. 20.
    Clement PB (2005) Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions. Mod Pathol 18(Suppl 2): S113–S129CrossRefPubMedGoogle Scholar
  21. 21.
    McCluggage WG, Wilkinson N (2005) Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 47:231–247CrossRefPubMedGoogle Scholar
  22. 22.
    Young RH (2007) From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol 14:149–177CrossRefGoogle Scholar
  23. 23.
    Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518PubMedGoogle Scholar
  24. 24.
    Kurman RJ, Shih Ie M (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151–160PubMedGoogle Scholar
  25. 25.
    Vang R, Shih Ie M, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16:267–282CrossRefPubMedGoogle Scholar
  26. 26.
    Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443CrossRefPubMedGoogle Scholar
  27. 27.
    Bell J, Brady M, Lage J et al (2003) A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 88:156CrossRefGoogle Scholar
  28. 28.
    du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO) Cancer 115:1234–1244PubMedGoogle Scholar
  29. 29.
    Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis. J Clin Oncol 20:1248–1259CrossRefPubMedGoogle Scholar
  30. 30.
    du Bois A, Reuss A, Harter P et al (2010) Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 28:1733–1739CrossRefPubMedGoogle Scholar
  31. 31.
    Earle CC, Schrag D, Neville BA et al (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98:172–180CrossRefPubMedGoogle Scholar
  32. 32.
    Du Bois A, Quinn M, Thigpen T et al (2005) 2004 Consensus statements on the management of ovarian cancer — final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16(Suppl)8:7–12Google Scholar
  33. 33.
    du Bois A, Lück H-J, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1330PubMedGoogle Scholar
  34. 34.
    Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 21:3194–3200CrossRefPubMedGoogle Scholar
  35. 35.
    Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691CrossRefPubMedGoogle Scholar
  36. 36.
    Vergote et al (2008) EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage III-IV ovarian, fallopian tube and peritoneal cancer. Personal communications at the 12th meeting of the International Gynecologic Cancer Society (IGCS) Bangkok, Thailand 2008Google Scholar
  37. 37.
    Martinek I, Kehoe S (2010) When should surgical cytoreduction in advanced ovarian cancer take place? J Clin Oncol doi: 10.1155/2010/852028Google Scholar
  38. 38.
    van der Burg MEL, van Lent M, Buyse M et al (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynaecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. NEJM 332:629–634CrossRefPubMedGoogle Scholar
  39. 39.
    Rose PG, Nerenstone S, Brady MF et al (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. NEJM 351:2489–2497, 2567CrossRefPubMedGoogle Scholar
  40. 40.
    Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P (2009) Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. Gynecol Oncol 112:257–264CrossRefPubMedGoogle Scholar
  41. 41.
    Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a metaanalysis. Gynecol Oncol 103:1070–1076CrossRefPubMedGoogle Scholar
  42. 42.
    Bookman Michael A, Brady Mark F, McGuire William P et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase iii trial of the Gynecologic Cancer InterGroup. J Clin Oncol 27:1419–1425CrossRefPubMedGoogle Scholar
  43. 43.
    González-Martín A (2007) Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: A new standard in patient care? Clin Transl Oncol 9:409–411CrossRefPubMedGoogle Scholar
  44. 44.
    Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955CrossRefPubMedGoogle Scholar
  45. 45.
    Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007PubMedGoogle Scholar
  46. 46.
    Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43CrossRefPubMedGoogle Scholar
  47. 47.
    Markman M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24:988–993CrossRefPubMedGoogle Scholar
  48. 48.
    Wenzel LB, Huang HQ, Armstrong DK et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25:437–443CrossRefPubMedGoogle Scholar
  49. 49.
    Walker JL, Armstrong DK, Huang HQ et al (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100:27–32CrossRefPubMedGoogle Scholar
  50. 50.
    Ozols RF, Bookman MA, Young RC et al (2006) Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103:1–6CrossRefPubMedGoogle Scholar
  51. 51.
    Gore M, du Bois A, Vergote I (2006) Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24:4528–4530CrossRefPubMedGoogle Scholar
  52. 52.
    Katsumata N, Yasuda M, Takahashi F et al, for the Japanese Gynecologic Oncology Group (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338CrossRefPubMedGoogle Scholar
  53. 53.
    Markman M, Liu PY, Moon J et al (2009) Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: followup of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114:195–198CrossRefPubMedGoogle Scholar
  54. 54.
    Winter WE 3rd, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–3627CrossRefPubMedGoogle Scholar
  55. 55.
    Sánchez-Muñoz A, Pérez-Ruiz E, Mendiola Fernández C, Alba Conejo E, González-Martín A (2009) Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. Clin Transl Oncol 11:589–95.CrossRefPubMedGoogle Scholar
  56. 56.
    González Martín A (2009) Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed. Clin Transl Oncol 11:559–560CrossRefPubMedGoogle Scholar

Copyright information

© Feseo 2010

Authors and Affiliations

  • Antonio González-Martín
    • 1
    Email author
  • Gemma Toledo
    • 2
  • Luis Chiva
    • 3
  1. 1.Medical Oncology DepartmentCentro Oncológico MD Anderson International EspañaMadridSpain
  2. 2.Pathology DepartmentCentro Oncológico MD Anderson International EspañaMadridSpain
  3. 3.Gynecologic Oncology DepartmentCentro Oncológico MD Anderson International EspañaMadridSpain

Personalised recommendations